667 related articles for article (PubMed ID: 25119042)
1. PRC2 loss amplifies Ras-driven transcription and confers sensitivity to BRD4-based therapies.
De Raedt T; Beert E; Pasmant E; Luscan A; Brems H; Ortonne N; Helin K; Hornick JL; Mautner V; Kehrer-Sawatzki H; Clapp W; Bradner J; Vidaud M; Upadhyaya M; Legius E; Cichowski K
Nature; 2014 Oct; 514(7521):247-51. PubMed ID: 25119042
[TBL] [Abstract][Full Text] [Related]
2. PRC2 loss amplifies Ras signaling in cancer.
Baude A; Lindroth AM; Plass C
Nat Genet; 2014 Nov; 46(11):1154-5. PubMed ID: 25352098
[TBL] [Abstract][Full Text] [Related]
3. Response and resistance to BET bromodomain inhibitors in triple-negative breast cancer.
Shu S; Lin CY; He HH; Witwicki RM; Tabassum DP; Roberts JM; Janiszewska M; Huh SJ; Liang Y; Ryan J; Doherty E; Mohammed H; Guo H; Stover DG; Ekram MB; Brown J; D'Santos C; Krop IE; Dillon D; McKeown M; Ott C; Qi J; Ni M; Rao PK; Duarte M; Wu SY; Chiang CM; Anders L; Young RA; Winer E; Letai A; Barry WT; Carroll JS; Long H; Brown M; Liu XS; Meyer CA; Bradner JE; Polyak K
Nature; 2016 Jan; 529(7586):413-417. PubMed ID: 26735014
[TBL] [Abstract][Full Text] [Related]
4.
Oppel F; Ki DH; Zimmerman MW; Ross KN; Tao T; Shi H; He S; Aster JC; Look AT
Dis Model Mech; 2020 Aug; 13(8):. PubMed ID: 32651197
[TBL] [Abstract][Full Text] [Related]
5. Enhancer reprogramming in PRC2-deficient malignant peripheral nerve sheath tumors induces a targetable de-differentiated state.
Kochat V; Raman AT; Landers SM; Tang M; Schulz J; Terranova C; Landry JP; Bhalla AD; Beird HC; Wu CC; Jiang Y; Mao X; Lazcano R; Gite S; Ingram DR; Yi M; Zhang J; Keung EZ; Scally CP; Roland CL; Hunt KK; Feig BW; Futreal PA; Hwu P; Wang WL; Lazar AJ; Slopis JM; Wilson-Robles H; Wiener DJ; McCutcheon IE; Wustefeld-Janssens B; Rai K; Torres KE
Acta Neuropathol; 2021 Sep; 142(3):565-590. PubMed ID: 34283254
[TBL] [Abstract][Full Text] [Related]
6. Transcriptional plasticity promotes primary and acquired resistance to BET inhibition.
Rathert P; Roth M; Neumann T; Muerdter F; Roe JS; Muhar M; Deswal S; Cerny-Reiterer S; Peter B; Jude J; Hoffmann T; Boryń ŁM; Axelsson E; Schweifer N; Tontsch-Grunt U; Dow LE; Gianni D; Pearson M; Valent P; Stark A; Kraut N; Vakoc CR; Zuber J
Nature; 2015 Sep; 525(7570):543-547. PubMed ID: 26367798
[TBL] [Abstract][Full Text] [Related]
7. Targeting EZH2 and PRC2 dependence as novel anticancer therapy.
Xu B; Konze KD; Jin J; Wang GG
Exp Hematol; 2015 Aug; 43(8):698-712. PubMed ID: 26027790
[TBL] [Abstract][Full Text] [Related]
8. PRC2 is recurrently inactivated through EED or SUZ12 loss in malignant peripheral nerve sheath tumors.
Lee W; Teckie S; Wiesner T; Ran L; Prieto Granada CN; Lin M; Zhu S; Cao Z; Liang Y; Sboner A; Tap WD; Fletcher JA; Huberman KH; Qin LX; Viale A; Singer S; Zheng D; Berger MF; Chen Y; Antonescu CR; Chi P
Nat Genet; 2014 Nov; 46(11):1227-32. PubMed ID: 25240281
[TBL] [Abstract][Full Text] [Related]
9. Transcriptional Dependencies in Diffuse Intrinsic Pontine Glioma.
Nagaraja S; Vitanza NA; Woo PJ; Taylor KR; Liu F; Zhang L; Li M; Meng W; Ponnuswami A; Sun W; Ma J; Hulleman E; Swigut T; Wysocka J; Tang Y; Monje M
Cancer Cell; 2017 May; 31(5):635-652.e6. PubMed ID: 28434841
[TBL] [Abstract][Full Text] [Related]
10. Therapeutic targeting of polycomb and BET bromodomain proteins in diffuse intrinsic pontine gliomas.
Piunti A; Hashizume R; Morgan MA; Bartom ET; Horbinski CM; Marshall SA; Rendleman EJ; Ma Q; Takahashi YH; Woodfin AR; Misharin AV; Abshiru NA; Lulla RR; Saratsis AM; Kelleher NL; James CD; Shilatifard A
Nat Med; 2017 Apr; 23(4):493-500. PubMed ID: 28263307
[TBL] [Abstract][Full Text] [Related]
11. NF1 deficiency causes Bcl-xL upregulation in Schwann cells derived from neurofibromatosis type 1-associated malignant peripheral nerve sheath tumors.
Park HJ; Lee SJ; Sohn YB; Jin HS; Han JH; Kim YB; Yim H; Jeong SY
Int J Oncol; 2013 Feb; 42(2):657-66. PubMed ID: 23292448
[TBL] [Abstract][Full Text] [Related]
12. The Role of Polycomb Repressive Complex in Malignant Peripheral Nerve Sheath Tumor.
Zhang X; Murray B; Mo G; Shern JF
Genes (Basel); 2020 Mar; 11(3):. PubMed ID: 32182803
[TBL] [Abstract][Full Text] [Related]
13. RNAi screen identifies Brd4 as a therapeutic target in acute myeloid leukaemia.
Zuber J; Shi J; Wang E; Rappaport AR; Herrmann H; Sison EA; Magoon D; Qi J; Blatt K; Wunderlich M; Taylor MJ; Johns C; Chicas A; Mulloy JC; Kogan SC; Brown P; Valent P; Bradner JE; Lowe SW; Vakoc CR
Nature; 2011 Aug; 478(7370):524-8. PubMed ID: 21814200
[TBL] [Abstract][Full Text] [Related]
14. Dual mTORC1/2 inhibition induces anti-proliferative effect in NF1-associated plexiform neurofibroma and malignant peripheral nerve sheath tumor cells.
Varin J; Poulain L; Hivelin M; Nusbaum P; Hubas A; Laurendeau I; Lantieri L; Wolkenstein P; Vidaud M; Pasmant E; Chapuis N; Parfait B
Oncotarget; 2016 Jun; 7(24):35753-35767. PubMed ID: 26840085
[TBL] [Abstract][Full Text] [Related]
15. Cancer research: Open ambition.
Maxmen A
Nature; 2012 Aug; 488(7410):148-50. PubMed ID: 22874946
[No Abstract] [Full Text] [Related]
16. Discovery of a small molecule targeting IRA2 deletion in budding yeast and neurofibromin loss in malignant peripheral nerve sheath tumor cells.
Wood M; Rawe M; Johansson G; Pang S; Soderquist RS; Patel AV; Nelson S; Seibel W; Ratner N; Sanchez Y
Mol Cancer Ther; 2011 Sep; 10(9):1740-50. PubMed ID: 21697395
[TBL] [Abstract][Full Text] [Related]
17. Super-enhancers define a proliferative PGC-1α-expressing melanoma subgroup sensitive to BET inhibition.
Gelato KA; Schöckel L; Klingbeil O; Rückert T; Lesche R; Toedling J; Kalfon E; Héroult M; Lejeune P; Mönning U; Fernández-Montalván AE; Bäurle S; Siegel S; Haendler B
Oncogene; 2018 Jan; 37(4):512-521. PubMed ID: 28991225
[TBL] [Abstract][Full Text] [Related]
18. Loss of PRC2 function promotes MPNST pathogenesis.
Cancer Discov; 2014 Nov; 4(11):OF14. PubMed ID: 25367955
[TBL] [Abstract][Full Text] [Related]
19. Dynamic Chromatin Targeting of BRD4 Stimulates Cardiac Fibroblast Activation.
Stratton MS; Bagchi RA; Felisbino MB; Hirsch RA; Smith HE; Riching AS; Enyart BY; Koch KA; Cavasin MA; Alexanian M; Song K; Qi J; Lemieux ME; Srivastava D; Lam MPY; Haldar SM; Lin CY; McKinsey TA
Circ Res; 2019 Sep; 125(7):662-677. PubMed ID: 31409188
[TBL] [Abstract][Full Text] [Related]
20. BRD4-targeted therapy induces Myc-independent cytotoxicity in Gnaq/11-mutatant uveal melanoma cells.
Ambrosini G; Sawle AD; Musi E; Schwartz GK
Oncotarget; 2015 Oct; 6(32):33397-409. PubMed ID: 26397223
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
